NCT04161482
An Open Label Study to Evaluate the Impact of Duration of Subcutaneous Infusion of a Novel, pH Neutral Formulation of Furosemide (Furoscix®) on Safety and Local Skin Tolerability
Phase: Phase 1
Role: Collaborator
Start: Dec 2, 2019
Completion: Jun 26, 2020